<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
November 28, 2000
---------------------------------
(Date of earliest event reported)
BIOLABS, INC.
--------------------------------------------------
(Exact name of Registrant as specified in charter)
New York 000-30252 98-0163232
--------------------------------------------------------------------------------
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
Suite 500, Park Place, 666 Burrard Street,
Vancouver, British Columbia, Canada V6C 2X8
--------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
(604) 669-0555
----------------------------------------------------
(Registrant's telephone number, including area code)
1A - 3033 King George Highway, Surrey, British Columbia, Canada V4P 1B8
-----------------------------------------------------------------------
(Former name or former address, if changed, since last report.)
Page 1 of 4 Pages
Exhibit Index on Page 4
<PAGE>
ITEM 5. OTHER EVENTS.
On November 28, 2000, BioLabs, Inc. announced that it will begin doing
business under the name Genesis Bioventures and plans to formally change its
corporate name to Genesis Bioventures as soon as it obtains shareholder
approval.
On November 29, 2000, BioLabs, Inc. announced that it had reorganized
its senior management team as follows:
Dr. Linda Allison was appointed as President and CEO effective
November 1, 2000;
Mr. Greg McCartney resigned as CEO but retains the position of
Chairman of the Board; and
Dr. Ian Woods was appointed as Medical & Scientific Advisor to the
Company.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) EXHIBITS
<TABLE>
<CAPTION>
Exhibit Number Description
-------------- -----------
<S> <C>
99.1 Press Release dated November 28, 2000.
99.2 Press Release dated November 29, 2000.
</TABLE>
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: December 6, 2000 BIOLABS, INC.
/s/ Linda Allison
-----------------------
Dr. Linda Allison
Chief Executive Officer
3
<PAGE>
EXHIBIT INDEX
<TABLE>
<CAPTION>
Exhibit Number Description Page Number
-------------- ----------- -----------
<S> <C> <C>
99.1 Press Release dated November 28, 2000.
99.2 Press Release dated November 29, 2000.
</TABLE>
4
